newsfilter
← Latest News
Business Wire·

Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026

Two-year SPARTAN data show 75% complete proteinuria remission and eGFR stabilization with first-line use of FILSPARI in IgANFILSPARI demonstrated approximately 3x higher complete proteinuria remission rates and 75%